Kiniksa Pharmaceuticals International plc-A 2025年季度报告

☒QUARTERLY REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedJune 30, 2025OR Kiniksa Pharmaceuticals International, plc(Exact Name of Registrant as Specified in Its Charter) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject tosuch filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company,or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerginggrowth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.◻ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act). Yes☐No☒As of July 25, 2025, there were74,107,668ordinary shares outstanding in aggregate, comprised of:43,472,928Class A ordinary shares, nominal value $0.000273235 per share1,795,158Class B ordinary shares, nominal value $0.000273235 per share12,781,964Class A1 ordinary shares, nominal value $0.000273235 per share16,057,618Class B1 ordinary shares, nominal value $0.000273235 per share Kiniksa Pharmaceuticals International,plc FORM10-Q FOR THE THREE MONTHS ENDED JUNE 30, 2025 TABLE OF CONTENTS Item1. Financial Statements (unaudited)7Consolidated Balance Sheets as of June 30, 2025 and December 31, 20247Consolidated Statements of Operations and Comprehensive Income (Loss) for the three andsix months ended June 30, 2025 and 20248Consolidated Statements of Shareholders’ Equity for the three and six months ended June 30,2025 and 20249Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 202410Notesto Consolidated Financial Statements11Item2. Management’s Discussion and Analysis of Financial Condition and Results ofOperations30Item3. Quantitative and Qualitative Disclosures About Market Risk43Item4. Controls and Procedures43 Item1. Legal Proceedings44Item1A. Risk Factors44Item2.Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of EquitySecurities107Item3.Defaults Upon Senior Securities107Item4.Mine Safety Disclosures107Item5.Other Information107Item6.Exhibits108 SIGNATURES110 SPECIAL NOTEREGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this “Quarterly Report”), contains forward-lookingstatements. All statements other than statements of historical facts contained in this Quarterly Reportincluding statements regarding our commercial strategy; potential value drivers; potential indications;potential market opportunities and competitive position; ongoing, planned and potential clinical trialsand other studies; timing and potential impact of clinical data; future results of operations andfinancial position; expected timeline for our cash, cash equivalents and short-term investments;product development; prospective products and product candidates; supply of drug products atacceptable cost and quality; collaborators, license and other strategic arrangements; the expectedtimeline for achievement of our clinical milestones; potential marketing authorizations from theUnited States Food and Drug Administration (the “FDA”) or regulatory authorities in otherjurisdictions; potential and ongoing coverage and reimbursement for our products and productcandidates, if approved; clinical and commercial activities; research and development costs; timing ofregulatory filings and feedback; timing and likelihood of success; and plans and objectives ofmanagement for future operations and funding requirements, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other importantfactors that may cause our actual results, performance or achievements to be materially different fromany future results, performance or achievements expressed or implied by the forward-lookingstatements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,”“should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “goal,” “design,” “target,” “project,”“co